Eli Lilly and Co LLY.N said on Thursday fewer deaths were reported among COVID-19 patients taking a combination of its rheumatoid arthritis drug and Gilead Sciences Inc’s GILD.O remdesivir in a clinical trial, compared to only remdesivir.
Lilly said the effect was most pronounced in patients on oxygen therapy, according to data from a U.S. government-backed trial, which however, was not designed to measure the effectiveness of baricitinib in preventing death.
In-line with data disclosed in September, the combination helped shorten the median recovery time by one day compared to remdesivir, meeting the study’s main goal.
Lilly said 5.1% of patients on the drug combination died after 29 days versus 7.8% patients given remdesivir, which is already authorized in the U.S. for treating COVID-19 patients, and a placebo.
https://www.reuters.com/article/us-health-coronavirus-lilly-arthritis-idUSKBN26T31CHELP US SPREAD GOOD NEWS!
I run this site in my spare time and thoroughly enjoy giving you all positive news! If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.
ENJOY FEEL GOOD, INSPIRING STORIES AND VIDEOS ?
Our new page here is just what you need, with just good news, feel good stories unrelated to COVID.
